Daniel Pichl - 02 Feb 2024 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)

Role
Chief People Officer
Signature
/s/ Francis I. Perier, Jr. as Attorney-in Fact
Issuer symbol
SWTX
Transactions as of
02 Feb 2024
Net transactions value
-$711,212
Form type
4
Filing time
05 Feb 2024, 21:23:02 UTC
Previous filing
08 Jan 2024
Next filing
20 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWTX Common Stock Options Exercise $449,150 +16,250 +29% $27.64 71,393 02 Feb 2024 Direct F1
transaction SWTX Common Stock Sale $405,942 -9,266 -13% $43.81 62,127 02 Feb 2024 Direct F1, F2
transaction SWTX Common Stock Sale $628,157 -14,175 -23% $44.31 47,952 02 Feb 2024 Direct F1, F3
transaction SWTX Common Stock Sale $91,756 -1,997 -4.2% $45.95 45,955 02 Feb 2024 Direct F1, F4
transaction SWTX Common Stock Sale $34,507 -743 -1.6% $46.44 45,212 02 Feb 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SWTX Stock Option (Right to Buy) Options Exercise $0 -16,250 -25% $0.000000 48,750 02 Feb 2024 Common Stock 16,250 $27.64 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 9, 2023.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.05 to $44.045. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.05 to $44.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.29 to $46.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.31 to $47.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 Twenty-five percent (25%) of this option shall vest and become exercisable on January 5, 2024, with the remaining seventy-five percent (75%) to vest in thirty-six (36) equal monthly installments thereafter subject to continued service to the Issuer by the Reporting Person.